Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Ischemic Stroke, Inflammation, and Endotheliopathy in COVID-19 Patients
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
016

Early reports suggest an increased risk of ischemic stroke during COVID-19 infection. We aimed to identify patients with COVID-19 and ischemic stroke and explore markers of endotheliopathy, inflammation, and hypercoagulability.

Novel coronavirus-19 disease (COVID-19) is associated with a diverse array of neurologic complications, including ischemic stroke. Suspected mechanisms include hypercoagulability and endothelial injury, although evidence is sparse in stroke patients.

This was a retrospective, observational cohort study of patients with acute ischemic stroke and COVID-19 (n=21) compared to non-COVID-19 acute ischemic stroke patients (n=11). Timing of stroke onset during COVID-19 course, acute phase reactant levels, cytokine levels, endothelial activation, and hypercoagulability were evaluated with respect to stroke onset and etiology.

Twenty-one ischemic stroke patients were diagnosed with COVID-19 during the study period. Both groups had a similar age and burden of vascular risk factors. COVID-19 patients had significantly higher levels of endothelial activation around the time of stroke when compared to controls. The mean Factor VIII level was 332% of normal in the COVID-19 group and 49% in the control group, while von Willebrand Factor antigen and activity were 330% and 285% in the COVID-19 group and 213% and 152% in the control group, respectively. Cytokine storming and a strong inflammatory responses are defining features of severe COVID-19. We demonstrated a temporal correlation between stroke onset and the peak of acute phase reactants. Elevated cytokine levels, IL-6 and soluble IL-2 receptor levels in particular, were significantly associated with embolic stroke of undetermined source (ESUS) in COVID-19 patients when compared with other etiologies.

We provide emerging evidence that endotheliopathy and the systemic inflammatory response in patients with vascular risk factors and COVID-19 is associated with ischemic stroke. Further research is needed. Understanding the mechanism of stroke in COVID-19 patients will be critical in providing primary stroke prevention and treatment.
Authors/Disclosures
Lindsay S. McAlpine, MD (Yale University)
PRESENTER
Dr. McAlpine has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Law Firm. The institution of Dr. McAlpine has received research support from NIH.
Adeel Zubair, MD (Yale University School of Medicine) Dr. Zubair has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The MedNet.
Ilavarasy Maran, MD (Trillium Health Partners) Dr. Maran has nothing to disclose.
Pola Chojecka, MD Dr. Chojecka has nothing to disclose.
Paul Eugene P. Lleva, MD, FÂé¶¹´«Ã½Ó³»­ (White Plains Hospital) Dr. Lleva has nothing to disclose.
Adam S. Jasne, MD (Yale) Dr. Jasne has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Dhasakumar S. Navaratnam, MD, PhD (Yale University, SOM, Neurology Dept) The institution of Dr. Navaratnam has received research support from NIH. The institution of Dr. Navaratnam has received research support from AHRA. Dr. Navaratnam has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with NIH.
Charles Matouk Charles Matouk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Silk Road Medical. Charles Matouk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Microvention. Charles Matouk has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Navigantis.
Joseph L. Schindler, MD (Yale University Department of Neurology) Dr. Schindler has received personal compensation for serving as an employee of Aeromics. Dr. Schindler has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Aeromics. Dr. Schindler has received stock or an ownership interest from Aeromics. Dr. Schindler has received publishing royalties from a publication relating to health care.
No disclosure on file
No disclosure on file
Serena Spudich, MD (Yale University) The institution of Dr. Spudich has received research support from NIH.
Richa Sharma, MD (Massachusetts General Hospital, Brigham, Harvard) Dr. Sharma has received research support from NIH. Dr. Sharma has received intellectual property interests from a discovery or technology relating to health care.
Lauren H. Sansing, MD Dr. Sansing has nothing to disclose.